v3 Template
O

OrsoBio, Inc.

Biotechnology / Healthcare ~280 employees
Founded
--
Employees (Est.)
~280
14 leaders known
Total Funding
$127.0M
Funding Rounds
2
Last Funding
2024-09-06

About OrsoBio, Inc.

OrsoBio is dedicated to developing novel therapies for patients with severe metabolic disorders such as obesity, diabetes, severe dyslipidemias, and NASH. Their mission is to redefine treatment by addressing the root causes of these disorders through first-in-class therapies targeting energy metabolism and homeostasis.

Products & Services

ACC2 Inhibitor (TLC-3595, TLC-3593):Selective Acetyl-CoA Carboxylase 2 (ACC2) inhibition to improve insulin sensitivity in patients with type 2 diabetes.
LXR Inverse Agonist (TLC-2716):Liver X Receptor (LXR) inhibition to improve plasma triglycerides, cholesterol, and hepatic steatosis in patients with severe dyslipidemias, hypertriglyceridemia, and NASH.
Mitochondrial Protonophore (TLC-6740, TLC-1180, TLC-1235):Mitochondrial protonophores to increase energy expenditure and improve metabolic and cardiovascular health in patients with obesity, lipodystrophies, and associated metabolic disorders.
ACMSD Inhibitor:ACMSD inhibition to augment NAD+ biosynthesis and improve mitochondrial function in patients with liver and/or kidney dysfunction due to metabolic and inflammatory disorders.

Specialties

Metabolic Disorders Energy Metabolism Obesity Treatment Diabetes Treatment Dyslipidemia Treatment NASH Treatment Mitochondrial Function Drug Development

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Series B
T: -
FT: Series B 		A: 67000000
MR: -
FA: $67 million
FAN: 67000000 		D: 2024-09-06
FD: 2024-09-06 		7 investors
2 RT: Series A
T: -
FT: Series A 		A: 60000000
MR: -
FA: $60 million
FAN: 60000000 		D: 2023-11-07
FD: 2023-11-07 		5 investors
Series B Latest
2024-09-06
$67.0M
7 investors (Pro only)
Series A 2023-11-07
$60.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

M

Mani Subramanian

CEO and Founder

R

Rob Myers

Chief Medical Officer and Head of Development

G

Gerald Shulman

Scientific Advisor

J

Johan Auwerx

Scientific Advisor

T

Takanori Takebe

Scientific Advisor

S

Srini Akkaraju

Director

View 11 more team members with Pro

Unlock Full Team Directory

Recent News

OrsoBio, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biotechnology / Healthcare
Company Size
~280 employees (est.)

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro